Spectral Medical Inc. (EDTXF) Research

Spectral Medical Inc., together with its associated companies, concentrates on developing and bringing to market healthcare solutions for septic shock and kidney disease patients across North America. The firm offers the Endotoxin Activity Assay (EAA), a quick in vitro diagnostic test that identifies components of gram-negative bacterial cell walls, and Polymyxin B Hemoperfusion (PMX), a therapeutic blood filtration device engineered to eliminate endotoxins from the bloodstream. Additionally, Spectral Medical Inc. produces various specialized biological components, including monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators. These are utilized internally for research and development, as well as supplied to other diagnostic manufacturers. The company is also actively developing a platform dedicated to renal replacement therapy. Originally founded in 1991, the company operated as Spectral Diagnostics Inc. before changing its name to Spectral Medical Inc. in December 2014. Its main corporate office is located in Toronto, Canada.

Open Spectral Medical Inc. (EDTXF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.